WASP-4 Is Accelerating toward the Earth Bouma, L. G.; Winn, J. N.; Howard, A. W. ...
Astrophysical journal. Letters,
04/2020, Volume:
893, Issue:
2
Journal Article
Peer reviewed
Open access
The orbital period of the hot Jupiter WASP-4b appears to be decreasing at a rate of −8.64 1.26 ms yr−1, based on transit-timing measurements spanning 12 yr. Proposed explanations for the period ...change include tidal orbital decay, apsidal precession, and acceleration of the system along the line of sight. To investigate further, we performed new radial-velocity measurements and speckle imaging of WASP-4. The radial-velocity data show that the system is accelerating toward the Sun at a rate of −0.0422 0.0028 m s−1 day−1. The associated Doppler effect should cause the apparent period to shrink at a rate of −5.94 0.39 ms yr−1, comparable to the observed rate. Thus, the observed change in the transit period is mostly or entirely produced by the line-of-sight acceleration of the system. This acceleration is probably caused by a wide-orbiting companion of mass 10-300 MJup and orbital distance 10-100 au, based on the magnitude of the radial-velocity trend and the nondetection of any companion in the speckle images. We expect that the orbital periods of one out of three hot Jupiters will change at rates similar to WASP-4b, based on the hot-Jupiter companion statistics of Knutson et al. Continued radial-velocity monitoring of hot Jupiters is therefore essential to distinguish the effects of tidal orbital decay or apsidal precession from line-of-sight acceleration.
Abstract
Kepler 1627A is a G8V star previously known to host a 3.8
R
⊕
planet on a 7.2 day orbit. The star was observed by the Kepler space telescope because it is nearby (
d
= 329 pc) and it ...resembles the Sun. Here, we show using Gaia kinematics, TESS stellar rotation periods, and spectroscopic lithium abundances that Kepler 1627 is a member of the
38
−
5
+
6
Myr old
δ
Lyr cluster. To our knowledge, this makes Kepler 1627Ab the youngest planet with a precise age yet found by the prime Kepler mission. The Kepler photometry shows two peculiarities: the average transit profile is asymmetric, and the individual transit times might be correlated with the local light-curve slope. We discuss possible explanations for each anomaly. More importantly, the
δ
Lyr cluster is one of ∼10
3
coeval groups whose properties have been clarified by Gaia. Many other exoplanet hosts are candidate members of these clusters; their ages can be verified with the trifecta of Gaia, TESS, and ground-based spectroscopy.
Abstract
Stellar positions and velocities from Gaia are yielding a new view of open cluster dispersal. Here we present an analysis of a group of stars spanning Cepheus (
l
= 100°) to Hercules (
l
= ...40°), hereafter the Cep-Her complex. The group includes four Kepler objects of interest: Kepler-1643 b (
R
p
= 2.32 ± 0.13
R
⊕
,
P
= 5.3 days), KOI-7368 b (
R
p
= 2.22 ± 0.12
R
⊕
,
P
= 6.8 days), KOI-7913 Ab (
R
p
= 2.34 ± 0.18
R
⊕
,
P
= 24.2 days), and Kepler-1627 Ab (
R
p
= 3.85 ± 0.11
R
⊕
,
P
= 7.2 days). The latter Neptune-sized planet is in part of the Cep-Her complex called the
δ
Lyr cluster. Here we focus on the former three systems, which are in other regions of the association. Based on kinematic evidence from Gaia, stellar rotation periods from TESS, and spectroscopy, these three objects are also ≈40 million years (Myr) old. More specifically, we find that Kepler-1643 is
46
−
7
+
9
Myr old, based on its membership in a dense subcluster of the complex called RSG-5. KOI-7368 and KOI-7913 are
36
−
8
+
10
Myr old, and are in a diffuse region that we call CH-2. Based on the transit shapes and high-resolution imaging, all three objects are most likely planets, with false-positive probabilities of 6 × 10
−9
, 4 × 10
−3
, and 1 × 10
−4
for Kepler-1643, KOI-7368, and KOI-7913, respectively. These planets demonstrate that mini-Neptunes with sizes of ≈2 Earth radii exist at ages of 40 Myr.
A TRANSITING JUPITER ANALOG Kipping, D. M.; Torres, G.; Henze, C. ...
Astrophysical journal/The Astrophysical journal,
04/2016, Volume:
820, Issue:
2
Journal Article
Peer reviewed
Open access
ABSTRACT Decadal-long radial velocity surveys have recently started to discover analogs to the most influential planet of our solar system, Jupiter. Detecting and characterizing these worlds is ...expected to shape our understanding of our uniqueness in the cosmos. Despite the great successes of recent transit surveys, Jupiter analogs represent a terra incognita, owing to the strong intrinsic bias of this method against long orbital periods. We here report on the first validated transiting Jupiter analog, Kepler-167e (KOI-490.02), discovered using Kepler archival photometry orbiting the K4-dwarf KIC-3239945. With a radius of , a low orbital eccentricity ( ), and an equilibrium temperature of K, Kepler-167e bears many of the basic hallmarks of Jupiter. Kepler-167e is accompanied by three Super-Earths on compact orbits, which we also validate, leaving a large cavity of transiting worlds around the habitable-zone. With two transits and continuous photometric coverage, we are able to uniquely and precisely measure the orbital period of this post snow-line planet (1071.2323 0.0006d), paving the way for follow-up of this K = 11.8 mag target.
Tissue morphogenesis requires dynamic intercellular contacts that are subsequently stabilized as tissues mature. The mechanisms governing these competing adhesive properties are not fully understood. ...Using gain- and loss-of-function approaches, we tested the role of p120-catenin (p120) and VE-cadherin (VE-cad) endocytosis in vascular development using mouse mutants that exhibit increased (VE-cadGGG/GGG) or decreased (VE-cadDEE/DEE) internalization. VE-cadGGG/GGG mutant mice exhibited reduced VE-cad-p120 binding, reduced VE-cad levels, microvascular hemorrhaging, and decreased survival. By contrast, VE-cadDEE/DEE mutants exhibited normal vascular permeability but displayed microvascular patterning defects. Interestingly, VE-cadDEE/DEE mutant mice did not require endothelial p120, demonstrating that p120 is dispensable in the context of a stabilized cadherin. In vitro, VE-cadDEE mutant cells displayed defects in polarization and cell migration that were rescued by uncoupling VE-cadDEE from actin. These results indicate that cadherin endocytosis coordinates cell polarity and migration cues through actin remodeling. Collectively, our results indicate that regulated cadherin endocytosis is essential for both dynamic cell movements and establishment of stable tissue architecture.
Patients with Parkinson's disease chronically treated with levodopa commonly have delayed or unpredictable onset of its benefits after oral intake. In this study, we assessed the safety and efficacy ...of CVT-301, a self-administered levodopa oral inhalation powder, for the treatment of patients with Parkinson's disease during off periods.
In this randomised, double-blind, placebo-controlled, phase 3 trial, patients were recruited at 65 sites in Canada, Poland, Spain, and the USA. Eligible participants were patients with Parkinson's disease aged 30–85 years, who had daily off periods of 2 h or longer and showed an improvement of 25% or greater in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score from off to on state after use of an oral levodopa plus a dopa-decarboxylase inhibitor combination. Patients were assigned (1:1:1) with a computer-generated randomisation code, in fixed blocks of six, to either CVT-301 60 mg, CVT-301 84 mg, or placebo. Spirometry results and modified Hoehn and Yahr disease stage at screening were used for stratification of treatment groups. Patients, the sponsor, and site personnel were masked to treatment assignment. Each study dose consisted of two capsules administered with an inhaler. Patients were instructed to use the study drug as needed for off periods, and could self-administer up to five doses per day. The primary endpoint was the change in UPDRS motor score from predose to 30 min postdose, assessed at week 12 during an in-clinic off period, in the CVT-301 84 mg group compared with the placebo group. Analysis was by intention to treat. Safety was assessed in all patients who received at least one dose of experimental treatment. This trial is registered with ClinicalTrials.gov, number NCT02240030.
Between Dec 4, 2014, and Aug 26, 2016, 351 patients were enrolled and randomly assigned to receive CVT-301 60 mg (115 patients), CVT-301 84 mg (120 patients), or placebo (116 patients). Of these, 339 received the assigned study treatment (CVT-301 60 mg, n=113; CVT-301 84 mg, n=114; placebo, n=112) and 290 completed the study (CVT-301 60 mg, n=96; CVT-301 84 mg, n=97; placebo, n=97). The least-squares mean difference in UPDRS motor score change from predose to 30 min postdose was −5·91 (SE 1·50, 95% CI −8·86 to −2·96) for the placebo group and −9·83 (1·51; −12·79 to −6·87) for the CVT-301 84 mg group (between-group difference −3·92 –6·84 to −1·00; p=0·0088). Treatments were safe and well tolerated. Severe adverse events were reported by 2 (2%) of 112 patients in the placebo group, 7 (6%) of 113 in the CVT-301 60 mg group, and 5 (4%) of 114 in the CVT-301 84 mg group, with no severe adverse event occurring in more than one patient in any treatment group. 11 (3%) of 339 patients had 19 serious adverse events (three 3% of 112 patients in placebo, six 5% of 113 in CVT-301 60 mg, and two 2% of 114 in CVT-301 84 mg). Of these, hypotension and atrial fibrillation were assessed by investigators to be possibly related to the study drug.
CVT-301 can improve UPDRS motor scores of patients with Parkinson's disease during in-clinic off periods, with few severe or serious adverse events. The long-term safety and efficacy of CVT-301 need to be investigated in future studies.
Acorda Therapeutics.
IMPORTANCE Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD). OBJECTIVE To ...determine the safety, tolerability, and urate-elevating capability of the urate precursor inosine in early PD and to assess its suitability and potential design features for a disease-modification trial. DESIGN, SETTING, AND PARTICIPANTS The Safety of Urate Elevation in PD (SURE-PD) study, a randomized, double-blind, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States. Seventy-five consenting adults (mean age, 62 years; 55% women) with early PD not yet requiring symptomatic treatment and a serum urate concentration less than 6 mg/dL (the approximate population median) were enrolled. INTERVENTIONS Participants were randomized to 1 of 3 treatment arms: placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation using 500-mg capsules taken orally up to 2 capsules 3 times per day. They were followed for up to 24 months (median, 18 months) while receiving the study drug plus 1 washout month. MAIN OUTCOMES AND MEASURES The prespecified primary outcomes were absence of unacceptable serious adverse events (safety), continued treatment without adverse event requiring dose reduction (tolerability), and elevation of urate assessed serially in serum and once (at 3 months) in cerebrospinal fluid. RESULTS Serious adverse events (17), including infrequent cardiovascular events, occurred at the same or lower rates in the inosine groups relative to placebo. No participant developed gout and 3 receiving inosine developed symptomatic urolithiasis. Treatment was tolerated by 95% of participants at 6 months, and no participant withdrew because of an adverse event. Serum urate rose by 2.3 and 3.0 mg/dL in the 2 inosine groups (P < .001 for each) vs placebo, and cerebrospinal fluid urate level was greater in both inosine groups (P = .006 and <.001, respectively). Secondary analyses demonstrated nonfutility of inosine treatment for slowing disability. CONCLUSIONS AND RELEVANCE Inosine was generally safe, tolerable, and effective in raising serum and cerebrospinal fluid urate levels in early PD. The findings support advancing to more definitive development of inosine as a potential disease-modifying therapy for PD. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00833690
ABSTRACT
We present the discovery and characterization of two transiting planets observed by TESS in the light curves of the young and bright (V = 9.67) star HD73583 (TOI-560). We perform an ...intensive spectroscopic and photometric space- and ground-based follow-up in order to confirm and characterize the system. We found that HD73583 is a young (∼500 Myr) active star with a rotational period of 12.08 ± 0.11 d, and a mass and radius of 0.73 ± 0.02 M⊙ and 0.65 ± 0.02 R⊙, respectively. HD 73583 b (Pb = $6.3980420 _{ - 0.0000062 } ^ { + 0.0000067 }$ d) has a mass and radius of $10.2 _{ - 3.1 } ^ { + 3.4 }$ M⊕ and 2.79 ± 0.10 R⊕, respectively, which gives a density of $2.58 _{ - 0.81 } ^ { + 0.95 }$ ${\rm g\, cm^{-3}}$. HD 73583 c (Pc = $18.87974 _{ - 0.00074 } ^ { + 0.00086 }$ d) has a mass and radius of $9.7 _{ - 1.7 } ^ { + 1.8 }$ M⊕ and $2.39 _{ - 0.09 } ^ { + 0.10 }$ R⊕, respectively, which translates to a density of $3.88 _{ - 0.80 } ^ { + 0.91 }$ ${\rm g\, cm^{-3}}$. Both planets are consistent with worlds made of a solid core surrounded by a volatile envelope. Because of their youth and host star brightness, they both are excellent candidates to perform transmission spectroscopy studies. We expect ongoing atmospheric mass-loss for both planets caused by stellar irradiation. We estimate that the detection of evaporating signatures on H and He would be challenging, but doable with present and future instruments.
Using Campaign 15 data from theK2mission, we have discovered a triply eclipsing triple star system: EPIC 249432662. The inner eclipsing binary system has a period of 8.23 d, withshallow∼3 per cent ...eclipses. During the entire 80-d campaign, there is also a single eclipse event of a third body in the system that reaches a depth of nearly 50 per cent and has a total duration of 1.7 d, longer than for any previously known third-body eclipse involving unevolved stars. The binary eclipses exhibit clear eclipse timing variations. A combination of photodynamical modeling of the light curve, as well as seven follow-up radial velocity measurements, has led to a prediction of the subsequent eclipses of the third star with a period of 188 d. A campaign of follow-up ground-based photometry was able to capture the subsequent pair of third-body events as well as two further 8-d eclipses. A combined photo-spectro-dynamical analysis then leads to the determination of many of the system parameters. The 8-d binary consists of a pair of M stars, while most of the system light is from a K star around which the pair of M stars orbits.
PDF
